3681 — Sinomab Bioscience Balance Sheet
0.000.00%
Last trade - 00:00- HK$1.47bn
- HK$1.87bn
- CNY2.03m
Annual balance sheet for Sinomab Bioscience, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 903 | 563 | 376 | 235 | 107 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 934 | 596 | 447 | 270 | 185 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 146 | 356 | 486 | 575 | 551 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,130 | 1,042 | 1,008 | 848 | 753 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 58.8 | 98.4 | 187 | 173 | 203 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 143 | 361 | 499 | 552 | 560 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 987 | 680 | 510 | 296 | 193 |
| Total Liabilities & Shareholders' Equity | 1,130 | 1,042 | 1,008 | 848 | 753 |
| Total Common Shares Outstanding |